CSB-001 Ophthalmic Solution for Corneal Scar

Recruiting in Palo Alto (17 mi)

+3 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Claris Biotherapeutics, Inc.

Disqualifiers: Active ocular infection, Ocular surgery, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests CSB-001 eye drops on people with new corneal scars. The drops are applied regularly to help heal the scars.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the effectiveness of the drug CSB-001 Ophthalmic Solution 0.1% for treating corneal scars?

Research shows that hepatocyte growth factor (HGF), a component of the drug, has protective effects on eye cells and can reduce damage in various eye conditions, suggesting it might help with corneal scars too. ^{1 2 3 4 5}

Is CSB-001 Ophthalmic Solution safe for humans?

The research articles do not provide specific safety data for CSB-001 Ophthalmic Solution or its related forms in humans. ^{3 6 7 8 9}

What makes CSB-001 Ophthalmic Solution unique for treating corneal scars?

CSB-001 Ophthalmic Solution is unique because it uses a modified form of hepatocyte growth factor (HGF), which has protective and healing properties, to potentially reduce corneal scarring. This approach is different from other treatments as it leverages the growth factor's ability to protect and repair cells, which is not a common mechanism in existing therapies for corneal scars. ^{1 3 4 5 9}

Research Team

Eligibility Criteria

This trial is for individuals with new corneal scars from an injury diagnosed within the last 7 to 30 days. Participants will use CSB-001 Ophthalmic Solution, a potential treatment for these scars.

Inclusion Criteria

I am willing and able to follow the study's procedures.

I have a scar on my eye close to the center, affecting my vision.

My eye was injured or infected between 1 to 4 weeks ago.

Exclusion Criteria

Maximum scar diameter greater than approximately 5 mm without prior approval by the Sponsor based on Screening Visit images

Any active ocular infection in the opinion of the investigator (bacterial, viral, fungal, or protozoal) at the Screening or Day 1 Visits. Subjects with an active bacterial infection at the Screening or Day 1 Visit in the opinion of the investigator may be rescheduled to reassess the status of the infection and continue in the study if infection is deemed not active

I am scheduled for eye surgery during the study.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive CSB-001 ophthalmic solution three or four times daily for up to 14 days

2 weeks

Daily dosing with clinic visits on Day 1, Day 7, and Day 14

Follow-up

Participants are monitored for safety and efficacy with assessments on Days 21, 28, 56, and Month 3

3 months

4 visits (in-person)

Treatment Details

Interventions

• CSB-001 Ophthalmic Solution 0.1% (Other)

Trial Overview The study tests CSB-001 Ophthalmic Solution's safety and effectiveness in treating corneal scars. Subjects apply the solution four times daily for up to two weeks, with follow-up visits extending to Day 56.

Participant Groups

Group I: CSB-001 TID Experimental Treatment 1 Intervention

One drop CSB-001 three times daily for 14 days in the study eye

Group II: CSB-001 QID Experimental Treatment 1 Intervention

One drop CSB-001 four times daily for 14 days in the study eye

Who Is Running the Clinical Trial?

Claris Biotherapeutics, Inc.

Lead Sponsor

Trials

3

Recruited

220+

Findings from Research

Diabetic patients with proliferative diabetic retinopathy (PDR) have significantly higher intravitreous concentrations of hepatocyte growth factor (HGF) compared to non-diabetic patients, indicating a potential role of HGF in the disease's progression.

The study found that the elevated levels of HGF in the vitreous of diabetic patients are not due to serum diffusion, suggesting that the eye synthesizes HGF locally, which may contribute to the development of PDR.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Cantón, A., Burgos, R., Hernández, C., et al.[2019]

Hepatocyte growth factor (HGF) protects retinal pigment epithelial (RPE) cells from oxidative injury caused by glutathione depletion, as evidenced by reduced apoptosis and increased levels of mitochondrial glutathione after HGF treatment.

HGF appears to enhance the expression of antioxidant genes and counteracts the activation of caspase-3 induced by oxidative stress, suggesting a mechanism where HGF helps maintain cellular health during oxidative challenges.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor protects RPE cells from apoptosis induced by glutathione depletion. Jin, M., Yaung, J., Kannan, R., et al.[2013]

In a study involving 24 New Zealand rabbits undergoing Epi-LASIK, higher levels of hepatocyte growth factor (HGF) in tears were associated with increased corneal haze, indicating a potential biomarker for post-surgical healing.

Rabbits with a deeper ablation of 150 µm exhibited more significant corneal haze and elevated HGF levels compared to those with a 100 µm ablation, suggesting that the depth of corneal ablation influences both healing response and haze formation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Association between hepatocyte growth factor in tears and corneal haze in rabbits early after epipolis laser in situ keratomileusis]. Chen, J., Han, SN., Zou, XL., et al.[2020]

References

1. England pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. [2019]

2. United States pubmed.ncbi.nlm.nih.gov

Deleted form of hepatocyte growth factor ameliorates the mortality rate of severe thermal injury in rats. [2017]

3. United States pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor protects RPE cells from apoptosis induced by glutathione depletion. [2013]

4. China pubmed.ncbi.nlm.nih.gov

[Association between hepatocyte growth factor in tears and corneal haze in rabbits early after epipolis laser in situ keratomileusis]. [2020]

5. United States pubmed.ncbi.nlm.nih.gov

Expression and neuroprotective effect of hepatocyte growth factor in retinal ischemia-reperfusion injury. [2009]

6. China pubmed.ncbi.nlm.nih.gov

Effect of human hepatocyte growth factor on promoting wound healing and preventing scar formation by adenovirus-mediated gene transfer. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Single low-dose administration of human recombinant hepatocyte growth factor attenuates intimal hyperplasia in a balloon-injured rabbit iliac artery model. [2019]

8. Poland pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor as a long‑term predictor for total and cardiovascular mortality in patients on peritoneal dialysis. [2019]

9. Greece pubmed.ncbi.nlm.nih.gov

Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells. [2009]